

The Royal Free London NHS Foundation Trust, National Amyloidosis Centre (NAC) and Alnylam UK (Alnylam) Joint Working Project: hATTR amyloidosis Therapeutic Review

Executive Summary

Alnylam and the NAC will enter a collaboration (Joint Working Agreement (JWA)) to increase the capacity of the NAC to support implementation of therapeutic reviews for adult patients with hATTR amyloidosis with stage 1 or stage 2 polyneuropathy. The prescribing HCP at the NAC will review each patient's current therapy and may elect to prescribe a different therapy that is more beneficial to the patient. This project will be independent of the prescription decision, which will be carried out by the prescribing HCP at the NAC.

The project will commence in April 2023. The project term is 12 months.

Expected benefits to patients, the NAC and Alnylam

Patients

It is expected that patients will benefit from improved outcomes and experiences from the accelerated therapeutic reviews with clinicians at the NAC. Patients changing therapy as a result of the therapeutic review will be provided with the support they need in relation to the new therapy they are prescribed.

NAC

The NAC will benefit from increased capacity to efficiently conduct a therapeutic review of all relevant patients. In addition to this, the project is expected to provide the NAC with some data to support a business case to be presented to NHS England for the future funding of a permanent TTR nurse role.

Alnylam

Alnylam is expected to benefit from the allocation of appropriate medicines to patients. Patients may receive appropriate Alnylam products if clinically indicated by the prescribing HCP at the NAC.

This document was originally produced by Alnylam and the NAC on March 1st, 2023.